Commissioner of Patents v Ono Pharmaceutical Co. Ltd & Anr [2022] FCAFC 39 Date:Court:Judges:18 March 2022Full Federal Court of AustraliaAllsop CJ, Yates and Burley...
Merck Sharp & Dohme & Anor v Sandoz Pty Ltd [2022] FCAFC 40 Date:Court:Judges:18 March 2022Full Federal Court of AustraliaAllsop CJ, Yates and Burley JJBackground...
14 Mar 22 | OcyonBio announced that it has entered into a manufacturing and operations agreement with Biosimilar Solutions Inc. to create a contract biosimilars...
Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first instance in their claim against Juno Pharmaceuticals Pty Ltd...
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week concerning allegations of patent infringement in respect of...
On 18 March 2022, the Full Court gave highly awaited judgments in two cases[1] concerning the validity of patent term extensions (PTEs) in Australia. Together, these judgments...
H. Lundbeck A/S v Sandoz Pty Ltd; CNS Pharma Pty Ltd v Sandoz Pty Ltd [2022] HCA 4Date:Court:Judges:9 March 2022High Court of AustraliaGaegler, Edelman, Steward and Gleeson...
Vector Corrosion Technologies Limited v E-Chem Technologies Ltd [2022] FCA 188 Date:Court:Judge:9 March 2022Federal Court of AustraliaJagot JBackground Vector Corrosion...
In this 55 minute Masterclass, a panel of award winning senior Pearce IP lawyers and patent attorneys discussed the strategic options available to challenge patent rights in Australia, and the ideal circumstances in which each option might be deployed.
03 Mar 22 | US | FDA announced a new funding opportunity for the BsUFA III Regulatory Science Program to support research projects that “enhance biosimilar and interchangeable...
As a female led boutique firm, Pearce IP celebrates the successes of its high achieving women on International Women’s Day. Each of Pearce IP’s CEO, and heads of litigation and...
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence will be able to apply to register a domain name of their...
18 Feb 22 | Celltrion released two data sets on the subcutaneous (SC) form of Remsima® (biosimilar infliximab). Celltrion reported that switching from IV to SC infliximab leads...
In this Boutique Lawyer Show podcast, Pearce IP’s CEO and Executive Naomi Pearce speaks candidly with Lawyers Weekly’s Jerome Doraisamy.
F45 Training Pty Ltd v Body Fit Training Company Pty Ltd (No 2) [2022] FCA 96 Date:Court:Judge:15 February 2022Federal Court of AustraliaNicholas JBackground F45 Training Pty Ltd...
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved...
UbiPark Pty Ltd v TMA Capital Australia Pty Ltd [2022] FCA 111 Date:Court:Judge:14 February 2022Federal Court of AustraliaMohinsky JBackground UbiPark Pty Ltd (UbiPark) and...
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs) in Australia: Biogen International GmbH v Pharmacor Pty Ltd...
07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a CEO Advisory Committee. Committee members represent Amneal...
Bayer Pharma Aktiengesellschaft [2022] APO 7Date:Venue:Delegate:7 February 2022Australian Patent OfficeKeith WraggBackground In our 2021 Patent Case summary, we reported on a...
01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of this division was primarily made possible through JAMP’s...
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft NMP was released by the National Medicines Policy Review...
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP was released by the National Medicines Policy Review...
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common stock. Alvotech and Oaktree Acquisition Corp. II...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
